SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma shines on plan to invest around Rs 1,300 crore towards capex

18 Nov 2014 Evaluate
Aurobindo Pharma is currently trading at Rs. 1141.20, up by 33.85 points or 3.06% from its previous closing of Rs. 1107.35 on the BSE.

The scrip opened at Rs. 1116.35 and has touched a high and low of Rs. 1147.25 and Rs. 1113.00 respectively. So far 56749 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1147.25 on 18-Nov-2014 and a 52 week low of Rs. 271.15 on 21-Nov-2013.

Last one week high and low of the scrip stood at Rs. 1147.25 and Rs. 1021.50 respectively. The current market cap of the company is Rs. 33192.00 crore.

The promoters holding in the company stood at 54.10% while Institutions and Non-Institutions held 35.67% and 10.22% respectively.

Aurobindo Pharma is planning to invest around Rs 1,300 crore towards capex during the ongoing and next financial years. The capex will be spread out across APIs (active pharmaceutical ingredients) and formulations and the company’s operations have resulted in substantial improvement to support the capex through internal cash generation.

Moreover, the pharma company spent around Rs 275 crore during the first half the current year. Meanwhile, consolidated net operating income of Aurobindo in second quarter of the ongoing fiscal grew 50 per cent to Rs 2,881 crore over the same period a year ago. Profit After Tax (after minority interest) was up by 58.4 per cent to Rs 372.2 crore during the July-September quarter against Rs 235 crore in the same quarter last fiscal. 

Aurobindo Pharma Share Price

1385.65 -0.45 (-0.03%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×